Rufinamide: a new antiepileptic drug treatment for Lennox–Gastaut syndrome

References

• Forsgren L, Hesdorffer D. Epidemiology and prognosis of epilepsy. In: The Treatment of Epilepsy (3rd Edition). Shorvon A, Perucca E, Engel J (Eds). Wiley-Blackwell, Oxford, UK 21–31 (2009).
   Google Scholar
• Beaumanoir A, Blume W. The Lennox–Gastaut syndrome. In: Epileptic Syndromes in Infancy, Childhood and Adolescence (4th Edition). Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P (Eds). John Libbey Eurotext, Montrouge, France 125–148 (2005).
   Google Scholar
• Morita DA, Glauser TA. Lennox–Gastaut syndrome. In: Pediatric Epilepsy: Diagnosis and Therapy (3rd Edition). Pellock JM, Bourgeois BFD, Dodson WE (Eds). Demos, NY, USA 307–334 (2008).
   Google Scholar
• Arzimanoglou A, French J, Blume WT et al. Lennox–Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol.8(1), 82–93 (2009).
   PubMed Web of Science ®Google Scholar
• Guerrini R, Parmeggiani L, Bonanni P, Kaminska A, Dulac O. Myoclonic astatic epilepsy. In: Epileptic Syndromes in Infancy, Childhood and Adolescence (4th Edition). Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P (Eds). John Libbey Eurotext, Montrouge, France 115–124 (2005).
   Google Scholar
• Trevathan E, Murphy CC, Yeargin-Allsopp M. Prevalence and descriptive epidemiology of Lennox–Gastaut syndrome among Atlanta children. Epilepsia38(12), 1283–1288 (1997).
   PubMedGoogle Scholar
• Ferrie CD, Patel A. Treatment of Lennox–Gastaut syndrome (LGS). Eur. J. Paed. Neurol.13(6), 493–504 (2009).
   Web of Science ®Google Scholar
• Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J. Child. Neurol.20(Suppl. 1), S1–S56 (2005).
   PubMedGoogle Scholar
• Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord.9(4), 353–412 (2007).
   PubMed Web of Science ®Google Scholar
• Hancock EC, Cross HH. Treatment of Lennox–Gastaut syndrome. Cochrane Database Syst. Rev.3, CD003277 (2009).
   Google Scholar
• McLean MJ, Scmutz M, Pozza M. The influence of rufinamide on sodium currents and action potential firing in rodent neurones. Epilepsia46(Suppl. 8), 296 (2005).
   Google Scholar
• Bialer M, Johannassen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (Eilat IV). Epilepsy Res.34(1), 1–41 (1999).
   PubMed Web of Science ®Google Scholar
• White HS, Franklin MR, Kupferberg HJ, Schmutz M, Stables JP, Wolf HH. The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia49(7), 1213–1220 (2008).
   Google Scholar
• Schmutz M, Allgeier H, Jeker A et al. Anticonvulsant profile of CGP 33101 in animals. Epilepsia32(Suppl. 2), 122 (1993).
   Google Scholar
• Jain KK. An assessment of rufinamide as an anti-epileptic in comparison with other drugs in clinical development. Exp. Opin. Invest. Drugs9(4), 829–840 (2000).
   PubMed Web of Science ®Google Scholar
• Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res.69(3), 273–294 (2006).
   PubMed Web of Science ®Google Scholar
• Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration–response relationships in patients with epilepsy. Epilepsia49(7), 1123–1141 (2008).
   PubMed Web of Science ®Google Scholar
• Critchley D, Fuseau E, Perdomo C, Arroyo S. Pharmacokinetic and pharmacodynamic parameters of adjunctive rufinamide in patients with Lennox–Gastaut syndrome. Epilepsia46(Suppl. 8), 209 (2005).
   Google Scholar
• Waldmeier F, Gschwind HP, Rouan MC, Sioufi A, Czendlik C. Metabolism of the new anticonvulsant trial drug rufinamide (CGP 33101) in healthy male volunteers. Epilepsia37(Suppl. 5), 167 (1996).
   Google Scholar
• Kapeghian JC, Madan A, Parkinson A, Tripp SL, Probst A. Evaluation of rufinamide (CGP 33101), a novel anticonvulsant, for potential drug interactions in vitro. Epilepsia37(Suppl. 5), 26 (1996).
   Google Scholar
• Arroyo S, Sachdeo R, Rosenfeld W, Critchley D, Perdemo C. Pharmacokinetics and safety of ascending doses of adjunctive rufinamide in pediatric patients with inadequately controlled seizures. Epilepsia46(Suppl. 8), 193 (2005).
   PubMedGoogle Scholar
• Chang SW, Choi L, Karolchyk MA. A pharmacokinetic evaluation of rufinamide in elderly and younger subjects. Epilepsia39(Suppl. 6), 59 (1998).
   Google Scholar
• Biton V. Rufinamide. In: The Treatment of Epilepsy (3rd Edition). Shorvon S, Perucca E, Engel J (Eds). Wiley-Blackwell, Oxford, UK 647–655 (2009).
   Google Scholar
• Fuseau E, Critchley D, Perdomo C, Arroyo S. Population pharmacokinetics drug–drug interaction analysis of rufinamide studies in patients with epilepsy. Epilepsia46(Suppl. 8), 210–211 (2005).
   Google Scholar
• Svendsen KD, Choi L, Chen BL, Karolchyk MA. Single center, open-label, multiple-dose pharmacokinetic trial investigating the effect of rufinamide administration on Ortho-Novum 1/35 in healthy women. Epilepsia39(Suppl. 6), 59 (1998).
   Google Scholar
• Pålhagen S, Canger R, Henriksen O, Van Parys JA, Rivière ME, Karolchyk MA. Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. Epilepsy Res.43(2), 115–124 (2001).
   PubMed Web of Science ®Google Scholar
• Elger C, Herman S, Perdomo C, Arroyo S. Dose-range relationships of rufinamide in patients with inadequately controlled partial seizures. Epilepsia46(Suppl. 8), 83–84 (2005).
   Google Scholar
• Todorov A, Biton V, Krauss GL, Perdomo C, Arroyo S. Efficacy and safety of high- versus low-dose rufinamide monotherapy in patients with inadequately controlled partial seizures. Epilepsia46(Suppl. 8), 218–219 (2005).
   Google Scholar
• Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome. Neurology70(21), 1946–1947 (2008).
   Google Scholar
• Biton V, Sachdeo R, Rosenfield W, Schachter S, Perdomo C, Arroyo S. Efficacy and safety of adjunctive rufinamide in patients with inadequately controlled primary generalised tonic–clonic seizures. Epilepsia46(Suppl. 8), 206 (2005).
   Google Scholar
• Kluger G, Glauser T, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox–Gastaut syndrome. Epilepsia47(Suppl. 3), 139 (2006).
   Google Scholar
• Kluger G, Kurlemann G, Haberlandt E. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav.14(3), 491–495 (2009).
   PubMed Web of Science ®Google Scholar
• Krauss GL, Perdomo CA, Arroyo S. Short and long-term safety of rufinamide in patients with epilepsy. Epilepsia46(Suppl. 8), 213 (2005).
   Google Scholar
• Aldenkamp A, Alpherts W. The effect of the new antiepileptic drug rufinamide on cognitive functions. Epilepsia47, 1153–1159 (2006).
   PubMed Web of Science ®Google Scholar
• Efficacy of felbamate in childhood epileptic encephalopathy (Lennox–Gastaut syndrome). The Felbamate Study Group in Lennox–Gastaut Syndrome. N. Engl. J. Med.328(1), 29–33 (1993).
   PubMed Web of Science ®Google Scholar
• Motte J, Trevathan E, Aevidsson JFV, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox–Gastaut syndrome. The Lamictal Lennox–Gastaut Study Group. N. Engl. J. Med.337(12), 1807–1812 (1997).
   PubMed Web of Science ®Google Scholar
• Fumisuke M, Riaz A. Lamotrigine. In: The Treatment of Epilepsy (3rd Edition). Shorvon S, Peruca E, Engel J (Eds). Blackwell Publishing, Oxford, UK 535–558 (2009).
   Google Scholar
• Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome. The Topiramate YL Study Group. Neurology52(9), 1882–1887 (1999).
   PubMed Web of Science ®Google Scholar
• Cross JH, Riney CJ. Topiramate. In: The Treatment of Epilepsy (3rd Edition). Shorvon S, Peruca E, Engel J (Eds). Blackwell Publishing, Oxford, UK 673–683 (2009).
   Google Scholar
• French J, Tonner F. Levetiracetam. In: The Treatment of Epilepsy (3rd Edition). Shorvon S, Peruca E, Engel J (Eds). Blackwell Publishing, Oxford, UK 559–573 (2009).
   Google Scholar
• Wroe JS. Zonisamide. In: The Treatment of Epilepsy (3rd Edition). Shorvon S, Peruca E, Engel J (Eds). Blackwell Publishing, Oxford, UK 713–720 (2009).
   Google Scholar
• Guerrini R, Belmonte A, Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia39(Suppl. 3), S2–S10 (1998).
   PubMed Web of Science ®Google Scholar
• Neal EG, Chaffe HM, Edwards N et al. The ketogenic diet in the treatment of epilepsy in children: a randomised, controlled trial (NCT00564915). Lancet Neurol.7(6), 500–506 (2008).
   PubMed Web of Science ®Google Scholar